文献速递慢性肾脏病肾血管病与高血压

强化血压控制对慢性肾脏病及不良结局风险患者的影响

Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes.
PubMed 文献 · J Am Soc Nephrol · 2023-01-17

该研究汇总7项试验的个体数据,评估强化血压控制(收缩压<120 mm Hg)对需要肾脏替代治疗的肾衰竭风险的影响。在5823例eGFR<60 ml/min per 1.73 m²的患者中,强化血压控制与肾脏结局风险降低相关但未达统计学显著;按基线eGFR分层,CKD 4-5期患者肾脏结局风险降低20%,而3期患者无此获益。

要点

  • 强化血压控制对CKD 4-5期患者延迟肾脏替代治疗启动可能有获益。
  • 强化血压控制对CKD 3期患者的肾脏结局未见获益。
  • 强化血压控制未显示伤害证据,但需针对晚期肾病患者的未来试验。

核心结论

  • 汇总7项试验的数据提示,强化血压控制对CKD 4-5期患者延迟肾脏替代治疗启动可能有获益,但对3期患者不一定有获益。
  • 这些发现提示强化血压控制无伤害证据,但也指出需要针对晚期肾病患者的未来血压目标试验。

研究设计与样本

  • 研究汇总7项试验的个体水平数据,纳入eGFR<60 ml/min per 1.73 m²的患者,共5823例参与者。
  • 预设亚组分析按基线白蛋白尿和eGFR(CKD 4-5期 vs 3期)评估强化血压控制的效果。

主要发现

  • 5823例参与者中,526例发生肾脏结局,382例死亡。
  • 总体分析中,强化(对比常规)血压控制与肾脏结局和死亡风险降低相关,但未达统计学显著。
  • 强化血压控制对肾脏结局的影响因基线eGFR而异(交互作用P=0.05)。
  • 意向性治疗分析中,CKD GFR 4-5期患者强化(对比常规)血压控制与主要肾脏结局风险降低20%相关,而CKD GFR 3期患者无此关联。
  • 强化血压控制与白蛋白尿严重程度对肾脏结局无交互作用。

局限性

  • 原文指出需要针对晚期肾病患者血压目标的未来试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: Although most guidelines recommend tightly controlling BP in patients with CKD, individuals with advanced kidney disease or severe albuminuria were not well-represented in trials examining the effect of this intervention on kidney outcomes. To examine the effect of intensive BP control on the risk of kidney outcomes in patients with CKD, the authors pooled individual-level data from seven trials. They found that overall, intensive BP control was associated with a 13% lower, but not significant, risk of a kidney outcome. However, the intervention's effect on the kidney outcome differed depending on baseline eGFR. Data from this pooled analysis suggested a benefit of intensive BP control in delaying KRT onset in patients with stages 4-5 CKD, but not necessarily in those with stage 3 CKD. BACKGROUND: The effect of intensive BP lowering (to systolic BP of <120 mm Hg) on the risk of kidney failure requiring KRT remains unclear in patients with advanced CKD. Such patients were not well represented in trials evaluating intensive BP control. METHODS: To examine the effect of intensive BP lowering on KRT risk-or when not possible, trial-defined kidney outcomes-we pooled individual-level data from seven trials that included patients with eGFR<60 ml/min per 1.73 m 2 . We performed prespecified subgroup analyses to evaluate the effect of intensive BP control by baseline albuminuria and eGFR (CKD stages 4-5 versus stage 3). RESULTS: Of 5823 trial participants, 526 developed the kidney outcome and 382 died. Overall, intensive (versus usual) BP control was associated with a lower risk of kidney outcome and death in unadjusted analyses but these findings did not achieve statistical significance. However, the intervention's effect on the kidney outcome differed depending on baseline eGFR ( P interaction=0.05). By intention-to-treat analysis, intensive (versus usual) BP control was associated with a 20% lower risk of the primary kidney outcome in those with CKD GFR stages 4-5, but not in CKD GFR stage 3. There was no interaction between intensive BP control and the severity of albuminuria for kidney outcomes. CONCLUSIONS: Data from this pooled analysis of seven trials suggest a benefit of intensive BP control in delaying KRT onset in patients with stages 4-5 CKD but not necessarily with stage 3 CKD. These findings suggest no evidence of harm from intensive BP control, but also point to the need for future trials of BP targets focused on populations with advanced kidney disease. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_02_27_JASN0000000000000060.mp3.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ku E, McCulloch CE, Inker LA, et al. Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes. J Am Soc Nephrol. 2023. PMID: 36735510. doi:10.1681/ASN.0000000000000072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。